Psoriasis

Biologic tildrakizumab-asmn approved with suffix as differentiator from future biosimilar versions.

A meta-analysis of 43,643 patients with multiple sclerosis shows that these patients have an increased incidence and prevalence of psoriasis.

The patient-provider relationship in psoriasis care is plagued by various disconnects, a review shows. Decision aids, interdisciplinary involvement may help.

Halobetasol propionate once a week for eight weeks in plaque psoriasis patients was effective, with no adverse events.

It can take weeks to achieve results after restarting biologic treatments that were stopped, study shows.

Wound healing is impaired in both psoriasis and multiple sclerosis. Understanding the pathophysiology of these two chronic conditions is vital to generating and improving treatment targets.

Patients with early-onset psoriasis are less likely than those with late-onset psoriasis to respond to systemic psoriasis treatments, a scientific review shows.

A review of more than 5,000 patients with moderate to severe plaque psoriasis who were treated with ixekizumab over three years, shows no unexpected safety signals.

Signs of aortic vascular inflammation in psoriasis patients may indicate early signs of coronary artery disease, report researchers writing in the Sept. 12 issue of JAMA Cardiology.

Psoriasis is associated with a host of comorbidities, such as obesity and the metabolic syndrome. In this study, researchers show that fatty liver disease is often the first sign of worsening health.

Researcher experiments with reformulating psoriasis topical as a lotion instead of cream, which performed well with patients.

Women in treatment for skin diseases, including psoriasis, experience higher levels of non-psychotic psychiatric disorders, including anxiety and depression, than men.

For women with psoriasis, psoriatic arthritis, and ankylosing spondylitis who take secukinumab during pregnancy or conception, recent research shows adverse pregnancy events don’t happen at a higher rate.

Developing psoriasis during childhood or adolescence can affect self-esteem. Dr. Amy Paller discussed the impact of psoriasis on adolescents, and treatment options, during the annual NPR Residents Meeting.

From obesity to heart disease, patients with psoriasis have a host of comorbidities and most rely on their dermatologist for comprehensive care.

For psoriasis patients, the most common comorbidity they may experience is psoriatic arthritis. Knowing how to identify and treat it can be critical.

Biologics certainly have shown to be an effective treatment in plaque psoriasis, but physicians should not discount more traditional therapies for treating psoriasis.

Understanding measures of psoriasis disease severity is critical for the patient. And, many payers, including the Centers for Medicare and Medicaid Service require an accurate PASI or PGA score on all psoriasis claims.

At the 20th annual National Psoriasis Foundation residents meeting recently held in Chicago, Dr. Abby Van Voorhees, said that phototherapy can improve psoriasis, but it is not in common practice today.

Nearly 80 percent of patients experience limited-to-moderate psoriasis disease, and topical therapies account for the majority, if not all, of their treatment. But the choice of topical treatment depends on the patient.

Two approved and two pending anti-IL 23 drugs offer an opportunity for moderate to severe psoriasis patients to regain their lives, according to researchers presenting at the 2018 Fall Clinical Dermatology Conference.

Reporting from Fall Clinical in Las Vegas, Dr. James Del Rosso reviews best practices for topical therapy uses in psoriasis and atopic dermatitis.

A novel tyrosine kinase 2 (TYK2) inhibitor may provide efficacy comparable to that of currently available biologic agents for psoriasis, without the adverse effects associated with JAK inhibitors, a study shows.

A recent review by the National Psoriasis Foundation's medical board suggests that adults with psoriasis and/or psoriatic arthritis (PsA) may use dietary interventions to supplement standard medical therapies to reduce disease severity.

Adalimumab trials in psoriasis show no new safety signals in nearly 5,500 patient-years (PYs) of exposure, shows a review in the British Journal of Dermatology.